Cigna earnings beat by $0.04, revenue topped estimates
In a recent transaction disclosed by Boston Scientific Corp. (NYSE:BSX), Vance R. Brown, the company’s Senior Vice President, General Counsel, and Corporate Secretary, sold 4,826 shares of common stock. The sale comes as the healthcare equipment giant, valued at $153.8 billion, trades near its 52-week high of $107.17, having delivered an impressive 60% return over the past year. The shares were sold on February 21, 2025, at a price of $104.64 per share, amounting to a total transaction value of $504,992.
Following this sale, Brown retains ownership of 45,845 shares. This transaction was executed under a pre-established Rule 10b5-1 trading plan, which Brown adopted in November 2024. The trading plan allows executives to sell a predetermined number of shares at a specified time, providing a defense against potential accusations of insider trading. For comprehensive insider trading analysis and 20+ additional exclusive insights, explore Boston Scientific’s detailed Pro Research Report on InvestingPro.
In other recent news, Boston Scientific Corporation reported strong financial results for 2024, with revenue reaching $16.7 billion, marking a 17.6% increase from the previous year. This growth surpassed the company’s initial guidance and was driven by successful product launches and strategic acquisitions. S&P Global Ratings and Fitch Ratings both upgraded Boston Scientific’s credit rating to ’A-’, reflecting the company’s robust operational performance and conservative financial policies. The company’s strategic focus on innovation and high-growth markets is expected to continue driving revenue growth and enhancing its market position.
Additionally, Boston Scientific announced that Charles J. Dockendorff will not seek re-election to its Board of Directors at the 2025 Annual Meeting, though this decision is not due to any disagreements with the company’s operations. On the analyst front, Stifel raised its price target for Boston Scientific shares to $120, maintaining a Buy rating, citing strong operating leverage opportunities and a positive outlook for 2025. RBC Capital Markets also increased its price target to $116, maintaining an Outperform rating, following the company’s robust fourth-quarter performance and strong guidance for 2025.
Boston Scientific’s commitment to innovation and strategic acquisitions remains a focal point, with the company expected to continue prioritizing research and development spending. The company’s financial policies are projected to remain conservative, with a focus on maintaining leverage targets and supporting growth through tuck-in acquisitions. These developments reflect Boston Scientific’s strong market position and potential for continued growth in the medical device sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.